Capital Management, Llcra C... Net Worth

The estimated Net Worth of Capital Management, Llcra C... is at least $33.7 Million dollars as of 15 April 2008. Capital C owns over 1,300,000 units of Curis Inc stock worth over $31,877,876 and over the last 17 years Capital sold CRIS stock worth over $1,820,000.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Capital C CRIS stock SEC Form 4 insiders trading

Capital has made over 1 trades of the Curis Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently Capital sold 1,300,000 units of CRIS stock worth $1,820,000 on 15 April 2008.

The largest trade Capital's ever made was selling 1,300,000 units of Curis Inc stock on 15 April 2008 worth over $1,820,000. On average, Capital trades about 1,300,000 units every 0 days since 2008. As of 15 April 2008 Capital still owns at least 6,250,564 units of Curis Inc stock.

You can see the complete history of Capital C stock trades at the bottom of the page.

Insiders trading at Curis Inc

Over the last 24 years, insiders at Curis Inc have traded over $10,321,234 worth of Curis Inc stock and bought 10,678,594 units worth $25,596,192 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Discovery Technologies Ltd ..., and James R Mcnab. On average, Curis Inc executives and independent directors trade stock every 62 days with the average trade being worth of $811,553. The most recent stock trade was executed by James E Dentzer on 27 January 2022, trading 5,500 units of CRIS stock currently worth $17,160.

What does Curis Inc do?

curis is a publicly-traded biotechnology company (nasdaq: cris) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. curis’s pipeline of drug candidates includes cudc-907, which is currently being investigating in clinical trials in patients with relapsed or refractory diffuse large b-cell lymphoma with alterations in the myc oncogene. curis is also engaged in a broad collaboration with aurigene in the areas of immuno-oncology and precision oncology. as part of this collaboration, curis has exclusive licenses to oral small molecule antagonists of the pd1 and vista pathways, including pdl1/vista antagonist ca-170, and oral small molecule antagonists of the pd1 and tim3 pathways, including pdl1/tim3 antagonist ca-327, as well as to molecules designed to inhibit the irak4 kinase, including ca-4948. ca-170 is currently undergoing testing in a phase 1 trial in patients with advanced solid tumors and lymphomas. ca-4948 is currentl

Complete history of Capital C stock trades at Curis Inc

Curis Inc executives and stock owners

Curis Inc executives and other stock owners filed with the SEC include:

• James Dentzer,
  President, Chief Executive Officer, Director
• James E. Dentzer,
  Pres, CEO & Director
• Robert Martell,
  Head - Research and Development
• William Steinkrauss,
  Chief Financial Officer
• Dr. Robert E. Martell,
  Head of R&D
• William E. Steinkrauss,
  Chief Financial Officer
• Martyn Greenacre,
  Independent Chairman of the Board
• Kenneth Kaitin,
  Independent Director
• Marc Rubin,
  Independent Director
• Lori Kunkel,
  Independent Director
• Elif McDonald,
  VP of Investor Relations & Corp. Communications
• Dr. Reinhard Wilhelm von Roemeling,
  Sr. VP of Clinical Devel.
• Mark W. Noel,
  VP of Technology Management & Intellectual Property
• John Hohneker,
  Director
• James R Mcnab,
  Director
• David Tuck,
  Chief Medical Officer
• Ali Ph.D. Fattaey,
  President & COO
• Kenneth Pienta,
  Director
• Discovery Technologies Ltd ...,
  
• Douglas Melton,
  Director
• Lee L Rubin,
  Senior Vice President,Research
• Mary Elizabeth Potthoff,
  Vice President,General Counsel
• Mani Mohindru,
  Sr. VP, Corp. Strategy & IR
• Christopher U Missling,
  Sr. Vice President, Finance
• Ruth B Kunath,
  Director
• Jaye Viner,
  Chief Medical Officer
• Michael Gray,
  Chief Financial Officer
• James R Tobin,
  Director
• Mark Noel,
  Vice President, Tech. Manage.
• Maurizio Voi,
  Chief Medical Officer
• Joseph Md Phd Davie,
  Director
• Susan B Bayh,
  Director
• Changgeng Qian,
  VP, Research & Preclinical Dev
• Capital Management, Llcra C...,
  
• Partners L P/Ilbiotechnolog...,
  
• Stephen Carter,
  Director
• Mitchell Keegan,
  Vice-President
• Joseph M Davie,
  Director
• Daniel R Passeri,
  President and CEO
• Anne Elizabeth Borgman,
  Director
• Diantha Duvall,
  CFO
• Jonathan B. Zung,
  CDO